New Q3 financing data reveals how these pressures are reshaping UK venture capital and exposing a fragile moment for the sector. The findings underscore the urgent need for sustained government action to unlock long-term growth capital and maintain the UK’s global competitiveness.
Our third quarter of has been focused on cementing and building upon our influence achieved in the key government policy documents that were published just before summer, such as the industrial Strategy and Life Sciences Sector Plan. Read on for a full breakdown of what they have been doing on your behalf.
Our latest TechBio: Future-ready biology report confirms a major structural shift in the UK life sciences sector: TechBio has moved from a niche field to the mainstream, accounting for over 40% of all UK biotech deals in recent years.
The UK’s life sciences sector has always been defined by its pioneering spirit. Today, that spirit is driving a revolution in medicine, with mRNA technology at its core. This report serves as a testament to the remarkable progress we have made in the UK, moving from a field of great promise to a strategic national asset.
The first half of 2025 has underscored the enduring appeal of UK biotech innovation, with total venture capital investment reaching £1.23 billion. This robust performance nearly matches the £1.25 billion raised across the entirety of 2023 and puts the sector half-way to matching the 2024 total.
This quarter has seen a cascade of government policy announcements, including the Spending Review and Industrial Strategy. Our team have been rigorously scrutinising and gearing up for the launch of the Life Sciences Sector Plan and the NHS 10-Year Health Plan, two transformative frameworks that could redefine the future of our sector.
This report from the BIA delves into the strategic importance of functional genomics, highlighting its potential to drive innovation across diverse applications, particularly in healthcare.
The UK has a vibrant ecosystem supporting early-stage life science start-ups, with accelerators helping companies raise significantly larger seed rounds and exit more efficiently. Our report highlights a critical gap: there is an urgent need for further support to help companies grow beyond scale, particularly given current headwinds. Addressing this is essential to sustain the UK’s global competitiveness in life sciences.
In 2035, we envision a UK biotech sector with a stronger long-term capital base supporting both early—and later-stage firms. To make Vision 2035 a reality, we, as a sector, must focus on areas that will have the greatest impact. Read the report to find out what those are!
UK biotech financing in Q1 2025 saw a sharp rise in overall equity financing, reaching £924 million across venture capital and follow-on funding. This represents a modest decline compared to £987 million in Q1 2024 but masks a shift in where capital is flowing.
The BIA has coined the term ‘Deep Biotech’ to capture companies working in this biotech space. This explainer explores the disruptive impact of biology-powered Deep Biotech products and processes, their role in tackling climate change, and how the BIA is driving forward the biorevolution in the UK.
Welcome to our new-look quarterly report, where the BIA team share examples of the influence we are delivering for members on government policy and the global life sciences ecosystem.
This report is the first step in understanding the specific challenges faced by female CEOs and C-suite in biotechnology in the UK – in order to understand best how we can help to enact change and provide relevant support.
Welcome to our new-look quarterly report, where the BIA team share examples of the influence we are delivering for members on government policy and the global life sciences ecosystem.
The UK biotech sector raised £3.5 billion in 2024, a 94% increase from the previous year, marking the highest level since 2021. Investment was concentrated in a few companies, with US investors leading the way.
The Department for Business and Trade (DBT) has produced the Genomics Spotlight 2024 to showcase the UK’s expertise in genomics and the latest developments that make the UK a hub for genomics business and investment.
The UK biotech sector demonstrated encouraging resilience in the third quarter of 2024 raising a total of £808 million in venture capital and public financing. Read our latest report to find out more.
Read the BIA's 2024 TechBio report to learn the current state of the sector and to read case studies from companies on the vanguard of innovation within the field.